Home › Acetylon's Selective HDAC Inhibitors To Be Featured In Multiple Presentations Of Positive Clinical And Preclinical Data At The 56th ASH Annual Meeting And Exposition
 

Keywords :   


Acetylon's Selective HDAC Inhibitors To Be Featured In Multiple Presentations Of Positive Clinical And Preclinical Data At The 56th ASH Annual Meeting And Exposition

2014-12-03 06:58:10| drugdiscoveryonline News Articles

Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes, recently announced that ricolinostat, the Company’s lead selective HDAC6 inhibitor, and selective HDAC1/2 inhibitors will be featured in one oral presentation and five posters at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 6-9, 2014, in San Francisco, CA

Tags: data featured multiple positive

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
03.07Nebraska celebrates new feedlot research, teaching, extension center
03.07Hurricane Beryl Public Advisory Number 20A
03.07Summary for Hurricane Beryl (AT2/AL022024)
03.07Eastern North Pacific Tropical Weather Outlook
03.07Atlantic Tropical Weather Outlook
03.07Genesus to restructure with Canada ZF Investments
03.07Global trade, domestic policy: What's at stake for pork industry
03.07Over 20,000 Tesco staff to split 30m from share schemes
More »